A new genomewide association study suggests that common variants associated with HS, located near the SOX9 and KLF5 genes, may raise the risk for the disease.
Two phase 3 studies with the IL-17 inhibitor bimekizumab for moderate-to-severe hidradenitis suppurativa generate clinically meaningful results, researchers report.